DK1096016T3 - Blodpladeaktiveringsfaktor-acetylhydrolase - Google Patents

Blodpladeaktiveringsfaktor-acetylhydrolase

Info

Publication number
DK1096016T3
DK1096016T3 DK00128728T DK00128728T DK1096016T3 DK 1096016 T3 DK1096016 T3 DK 1096016T3 DK 00128728 T DK00128728 T DK 00128728T DK 00128728 T DK00128728 T DK 00128728T DK 1096016 T3 DK1096016 T3 DK 1096016T3
Authority
DK
Denmark
Prior art keywords
activating factor
factor acetylhydrolase
platelet activating
platelet
acetylhydrolase
Prior art date
Application number
DK00128728T
Other languages
English (en)
Inventor
Laurence S Cousens
Trong Hai Le
Christine D Eberhardt
Larry W Tjoelker
Cheryl L Wilder
Patrick W Gray
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of DK1096016T3 publication Critical patent/DK1096016T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
DK00128728T 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase DK1096016T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13380393A 1993-10-06 1993-10-06
EP94930623A EP0673426B1 (en) 1993-10-06 1994-10-06 Platelet-activating factor acetylhydrolase

Publications (1)

Publication Number Publication Date
DK1096016T3 true DK1096016T3 (da) 2006-05-29

Family

ID=22460373

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94930623T DK0673426T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase
DK00128728T DK1096016T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK94930623T DK0673426T3 (da) 1993-10-06 1994-10-06 Blodpladeaktiveringsfaktor-acetylhydrolase

Country Status (12)

Country Link
US (5) US5641669A (da)
EP (3) EP1096016B1 (da)
JP (3) JP3613398B2 (da)
AT (2) ATE201905T1 (da)
CA (1) CA2151045C (da)
DE (2) DE69434609T2 (da)
DK (2) DK0673426T3 (da)
ES (2) ES2159573T3 (da)
GR (1) GR3036535T3 (da)
HK (2) HK1012023A1 (da)
PT (1) PT673426E (da)
WO (1) WO1995009921A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy
JP3563091B2 (ja) * 1993-08-03 2004-09-08 第一サントリーファーマ株式会社 酸化リン脂質分解酵素およびその遺伝子
US6146625A (en) * 1993-10-06 2000-11-14 Icos Corporation Platelet-activating factor acetylhydrolase
EP0859834A2 (en) * 1995-09-29 1998-08-26 Smithkline Beecham Plc A paf-acetylhydrolase and use in therapy
AU3572895A (en) * 1995-09-29 1997-04-28 Smithkline Beecham Plc Compound having sequence homology with lipoprotein associated phospholipase a2 (lp-pla2)/paf acetyl hydrolase
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
US6891084B1 (en) * 1996-04-26 2005-05-10 Ajinomoto Co., Inc. DNA encoding raffinose synthase from soybean
US6166292A (en) * 1996-04-26 2000-12-26 Ajinomoto Co., Inc. Raffinose synthetase gene, method of producing raffinose and transgenic plant
TR199802160T2 (xx) * 1996-04-26 1999-04-21 Smithkline Beecham Plc Ateroskleroz tedavisi i�in azetidinon t�revleri.
JPH1017600A (ja) * 1996-06-28 1998-01-20 Suntory Ltd 血小板活性化因子アセチルヒドロラーゼおよびその遺伝子
BR9711882A (pt) * 1997-08-13 1999-09-21 Icos Corp Fragmento, variante ou fragmento de variante de polipeptídeo de acetilidrolase (paf-ah), polinucleotídeo isolado, vetor de dna, célula hospedeira transformada ou transfectada com um dna, processo para a produção de um fragmento, variante ou fragmento de variante de polipeptídeo de paf - ah de plasma, composição farmacêutica, e, processo para tratar um mamífero suscetível a, ou sofrendo de, um quadro patológico mediado por paf.
JP2002528084A (ja) * 1998-10-28 2002-09-03 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 固定化金属アフィニティークロマトグラフィーを用いる低密度リポタンパク質関連ホスホリパーゼａ２の精製方法
GB9923790D0 (en) * 1999-10-08 1999-12-08 Isis Innovation Immunoregulatory compositions
CA2400554C (en) * 2000-02-16 2009-04-07 Smithkline Beecham P.L.C. Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
GB0024808D0 (en) 2000-10-10 2000-11-22 Smithkline Beecham Plc Novel compounds
GB0027181D0 (en) * 2000-11-04 2000-12-27 S P A New use
US7468266B2 (en) * 2001-05-30 2008-12-23 Ryogen, Llc Isolated genomic polynucleotide fragments that encode human lipoprotein-associated phospholipase A2
US7475248B2 (en) 2002-04-29 2009-01-06 International Business Machines Corporation Enhanced message security
US7273620B1 (en) 2002-05-20 2007-09-25 University Of British Columbia Triggered release of liposomal drugs following mixing of cationic and anionic liposomes
SI1633864T1 (sl) 2003-05-28 2010-07-30 Glaxo Group Ltd Visokozmogljivostni test lp-pla2 aktivnosti
ES2416344T3 (es) 2004-02-03 2013-07-31 Diadexus, Inc. Métodos para determinar la actividad de Lp-PLA2.
WO2005113797A2 (en) 2004-04-16 2005-12-01 Glaxo Group Limited METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP2007145814A (ja) * 2005-10-28 2007-06-14 Bizen Chemical Co Ltd 血小板活性化因子受容体拮抗剤および組成物
MX2008013394A (es) * 2006-04-21 2008-10-31 Wyeth Corp Metodos para tamizado de alta emision de lineas celulares.
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
JP5277243B2 (ja) 2007-05-11 2013-08-28 トーマス・ジェファーソン・ユニバーシティ 神経変性疾患および障害を治療および阻止する方法
US8257697B2 (en) 2007-10-31 2012-09-04 Allertech Laboratory Inc. Use of platelet activating factor acetylhydrolase as biomarker for anaphylaxis
JP2009005705A (ja) * 2008-07-02 2009-01-15 Icos Corp 血小板活性化因子アセチルヒドロラーゼ
JP5596964B2 (ja) * 2008-12-02 2014-09-24 協和メデックス株式会社 リポ蛋白中成分の分別定量用標準品の製造方法
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
CN105542010B (zh) * 2015-12-31 2020-11-03 武汉华美生物工程有限公司 脂蛋白相关磷脂酶a2单克隆抗体、抗体对及制备方法、用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5019508A (en) * 1987-08-27 1991-05-28 Biotechnology Research Partners, Ltd. Synovial phospholipases
US6565841B1 (en) * 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5279957A (en) * 1992-04-30 1994-01-18 Washington University cDNA encoding human phospholipase A2 polypeptide
GB9313144D0 (en) 1993-06-25 1993-08-11 Smithkline Beecham Plc Compounds
GB9400413D0 (en) 1994-01-11 1994-03-09 Smithkline Beecham Plc Compounds
WO1995000649A1 (en) * 1993-06-25 1995-01-05 Smithkline Beecham Plc Lipoprotein associated phospholipase a2, inhibitors thereof and use of the same in diagnosis and therapy

Also Published As

Publication number Publication date
US5532152A (en) 1996-07-02
EP0673426B1 (en) 2001-06-06
US5641669A (en) 1997-06-24
EP1096016A1 (en) 2001-05-02
EP1634953A3 (en) 2006-06-28
CA2151045C (en) 2002-04-30
US20050100540A1 (en) 2005-05-12
EP0673426A1 (en) 1995-09-27
ATE201905T1 (de) 2001-06-15
US5698403A (en) 1997-12-16
HK1038587A1 (en) 2002-03-22
DK0673426T3 (da) 2001-08-27
JP3613398B2 (ja) 2005-01-26
DE69427392D1 (de) 2001-07-12
JP3759941B2 (ja) 2006-03-29
CA2151045A1 (en) 1995-04-13
ES2258955T3 (es) 2006-09-16
US5605801A (en) 1997-02-25
DE69434609T2 (de) 2006-09-21
PT673426E (pt) 2001-11-30
EP1634953A2 (en) 2006-03-15
EP1096016B1 (en) 2006-01-11
GR3036535T3 (en) 2001-12-31
JP2006056901A (ja) 2006-03-02
JPH08504603A (ja) 1996-05-21
DE69434609D1 (de) 2006-04-06
JP2004129671A (ja) 2004-04-30
ATE315655T1 (de) 2006-02-15
DE69427392T2 (de) 2002-05-23
HK1012023A1 (en) 1999-07-23
WO1995009921A1 (en) 1995-04-13
ES2159573T3 (es) 2001-10-16

Similar Documents

Publication Publication Date Title
DK0673426T3 (da) Blodpladeaktiveringsfaktor-acetylhydrolase
ATE155143T1 (de) 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
FI943363A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten /1,4/oksatsino/3,4-a//2/bentsatsepiinijohdannaisten valmistamiseksi
ATE143972T1 (de) 2-substituierte indane-2-carboxyalkyl- verbindungen mit enkephalinase und ace- hemmwirkung
DE68928734D1 (de) Verfahren zur Herstellung alternierende Kristallstrukturen aufweisender thermoplastischer Elastomere als Bindemittel in Hochenergiezusammensetzungen
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
DE3888360D1 (de) Hochspannungsschalter und verfahren zur ansteuerung von verbrauchern mittels des hochspannungsschalters.
DE69330807D1 (de) Verfahren zur Herstellung von gereinigtem Enzym
DE69315370D1 (de) Herstellung von rauhen Silizium-Oberflächen
IL106748A0 (en) 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
CA2267994A1 (en) Truncated platelet-activating factor acetylhydrolase
EP0244361A3 (en) Individual beta-form crystals of tetrakis-û3-(3,5-di-t-butyl-4-hydroxyphenyl)-propionyloxymethyl¨ methane and process for their manufacture
ATA247988A (de) Vormaterial fuer die erzeugung von verbundwerkstoffen
IT9021986A0 (it) Procedimento e mezzi per la produzione continua di corpi di carbone
DK75393D0 (da) Production of protein
DE69427794D1 (de) Verbesserungen an Erdmühlen zur Herstellung von Terrakotta-Produkten
DE69432042D1 (de) Verfahren zum Screenen von Agenzien zur Prophylaxis oder Therapie von mit IgE zusammenhängenden Krankheiten
IL101743A0 (en) 2-mercaptomethylene-tetrahydronaphthalene and indane-2-carboxamide derivatives as enkephalinase inhibitors
FR2772231B1 (fr) Obtention de mutants cleistogames de cruciferes
DE69416663D1 (de) Verfahren zur Herstellung von menschlichem Glicentin
ITMI931527A0 (it) Procedimento e manufatto semilavorato per la produzione di calze- mutande
ITVI920198A1 (it) Ciclo di lavorazione per la produzione di pelli tipo nabuk
LV10483A (lv) Dzirkstoso vinu razosanas panemiens
LV10638A (lv) Dzirkstoso vinu razosanas panemiens
IT1286595B1 (it) Procedimento per la produzione di monili comprendenti pietre infilzate